Shield Therapeutics Share Discussion Threads

[lako42] 16/12/2020 19:50

Good post Peachie. I'm not ruling out returning once a few key things have been settled. The product is sound and will hopefully find the right people to bri g it to the masses... One day

[peachie 74] 16/12/2020 19:46

Good luck Lako

The product is too exclusively good to fail. Business is business and doesn’t always run smooth. This really hasn’t.

But is Iron deficiency still huge ..... yes
Is an alternative to IV still needed .. yes
Is there a competitor .... no
Have we a patent .....yes

The CEO may not be a performer. He may not be a great CEO. But I still believe the company know the value here and if it takes longer , so be it. Impatient investors won’t like it. Of course we all want our investment to do well.

But I believe this will ultimately be a big part of iron replacement therapy worldwide.

If you don’t , or believe Tim and the board can’t deliver , do like Lako and invest elsewhere. Simple. I’m staying. Well I’ve actually added at 62p. By next summer this will a lot higher. IMHO. But GL all , whatever your view.

[frrinvest] 16/12/2020 19:41

It was just a comment to highlight the safety, efficacy and scope of the product that ticks all boxes. I also mentioned "setting up sales infrastructure", without which you can't do much. Perhaps they were too confident or even their expectations for upfront fees and royalties were too high. We don't know what went on behind closed doors. They must have wanted to maximise shareholder value. World shutting down didn't help did it? Maybe the previous CEO wanted to go it alone but he didn't get the support so he left. Now they have come full circle. However, I do believe they have learnt a lot about the US market over the past 18 months and feel confident with an experienced US team they can succeed. Lots of speculation but we don't know the facts for sure. Lets hope they have learnt and can move on with a new CEO. One thing is for sure there is still a lot of value in STX imho.

[lako42] 16/12/2020 19:21

So are you saying it isn't a great product then seeing as it hasn't sold itself despite is spending 14 months a tively trying to?


Can't trust the board I'm afraid. I think it will be easier to get back the losses elsewhere so that's the end of the road for me.

GL all

[frrinvest] 16/12/2020 19:04

It looks like small pi's have sold here and hoping to buy back cheaper with their very negative and inaccurate comments regarding STX strategy. CLEARLY, The company have the backing of their major shareholders before TW's presentation. The two major ones have NDAs so can't trade anyway as he said. They are not bothered about small time sellers here. I should think small shares will be hoovered up anyway. just look at the volume of trades, so low. My confidence is in the product. The rest is about setting up sales infrastructure. This is what business is all about, a great product will sell itself.

[onceaday] 16/12/2020 18:55

I was reasonably happy with what he had to say. He seems to be trying to maximise value for shareholders. His point that there is risk in handing control to a poorly performing licensee makes sense. This seems to be demonstrated by the relationship with Norgine. I am inclined to agree that fronting the product in combination with targeted sub-licensing/co-promotion makes financial sense.

[powerp2] 16/12/2020 18:55

First 16 minutes waffle telling us what we already know and then 12 minutes on commercialisation failure - a lot of waffle later on too then they run out of time!
TW a waste of time and is not running the show. Who is?
Last time he said we wouldn't be diluted as any finance would be debt.
Well short term requirement are convertible loans so we'll see. In terms of bigger money he's now saying 50;50 debtequity.
He knew big pharmacist not interested in the summer when he was giving us the deal will be done before year end line.
The story 're company A and B didn't smell right to me.
Point on HIF inhibitor if true why wouldn't AstraZeneca run along with accrued for the full package?
Paediatric study - if we don't have the cash to we have regulatory issues is my understanding - if so company collapses and someone picks up for pennies - one of existing large shareholders?
I'm very worried mostly because I now don't trust the senior manager and don't know who really owns the agenda.

[ekcs] 16/12/2020 18:41

Perhaps Norgine might buy the whole thing (avoid royalties) and flog the US licence themselves?

Guess that assumes they are making good progress... and remain interested...

[frrinvest] 16/12/2020 18:25

TW is not the greatest of presenters, we know that. But he gave projected figures for going alone...if they capture only 2% of US iron deficient market then they are in the hunt. Not unsurmountable at all. May not be interest from Big Pharmas but by US standards even small pharmas are big by our standards. The two companies they are talking to have come back for further talks and they are not small from what he stated.

They are setting up an experienced executive team in USA. The two major shareholders are on board with their renewed strategy. Out-licencing is still a possibility in Q1 2021. So any movement in the USA will help the share price a great deal as he said "over-reaction to the RNS" and the current valuation does not take anything into consideration for the potential deal in the states. Product is great and has traction, "huge potential", he kept saying. You never know they may even get an offer for an outright sell and they won't say no it would appear. In any case I think he will be replaced as the CEO fairly quickly. So I see plenty of positives and the fact that they have already recruited "4 experienced USA commercial executives" with a view to launch in Q2 2021 means they are serious and this strategy cannot be overlooked. This is the take away for me. Also not how he said but the contents of his presentation had substance in moving forward. This gives them all the options at least.

[parc1] 16/12/2020 18:23

Surely Teva would be interested? Teva were trying to claim the product for themselves so they would have sold it for sure. They fought for it in court. There must be a deal there?

[lovewinshatelosses] 16/12/2020 18:22

It seems like I did well to avoid attending this presentation! Really disappointing, by the sound of it.
Has anyone changed their stance and now plan to sell up after listening to it?
I was ready to buy more around 55p (rather than my premature 65p the other day) but now have pause for thought.
Hmmm....

[best1467] 16/12/2020 18:21

Well i commented on Tim several months ago he is a finance guy not a CEO.
I have 3 major issues with what I listened too 1st the reasons given for the late failure of the two companies made no sense and is clearly in my opinion not believable
2nd You would have thought the need for more urgency as to the chosen path after 18 months and yet we have to wait another 3 months 3 rd he was asked the question twice and I have mentioned on this thread the lack of apparent communication with Nordgine on the current sales progress and he refused to comment.
While the product clearly as great potential I feel we will endure further weakness as the 50% fundraise will be sub 50p and the big holders will already know the price so will continue to off load

[whatno] 16/12/2020 18:12

I understand his point that there is also risk associated with a poor performing licensee. The point is rammed home by the fact that he can't answer questions relating to Norgine in Europe. If they build the right team in the US and don't try to skimp on the finances then they control the risk and have every chance of success. They screwed up in Europe because they ran out of money. Don't make the same mistake again Tim!

[parc1] 16/12/2020 18:04

Some "have a go" smaller companies want to sell it but obviously a no go for Shield to the extent of Shield going it alone rather than going down that route.

Key take away: 'Minimal interest from “Big Pharma” companies'

[powerp2] 16/12/2020 18:00

Waggle i thought the same thing!

[ekcs] 16/12/2020 17:57

I know it is hard at times but people need to do their best to get past his presentation capabilities or lack thereof... and try to see the detail in the presentation. That element is not going to change.

According to company announcements he signed a one year contract when Carl left and he's clearly said they have US-based people lined up if they do it themselves, so he is a caretaker. He is NOT going to lead the US push

More importantly for me the company needs to decide what is it to be as even during the presentation it wasn't clear what their preference is... SO please decide to commercialise or licence and commit to it without yet more delay and follow that through to fruition (or failure) AND critically make the decision clear in positive proactive communications to shareholders and the wider market as the last week's debacle is simply not acceptable.

[powerp2] 16/12/2020 17:50

I've put a few questions out and he's ignored some
Strong feeling that people don't believe him anymore

[t0pgrader] 16/12/2020 17:49

Yes I noticed the side step. He didnt address my q about the inexperience of the BoD

[t0pgrader] 16/12/2020 17:46

He is not qualified to lead the US team of consultants. I like the story but not the CEO.

[waggle] 16/12/2020 17:44

he is an appalling presenter and does not seem to realise that his sitting on the fence until at least the end of the first quarter iro license or direct is the worst of both worlds?

[t0pgrader] 16/12/2020 17:42

Just implausible that the company proceeds alone in USA with this CEO